Cerity Partners’s BeOne Medicines Ltd ONC Stock Holding History

Cerity Partners’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$587K	Sell	2,059 -99	-5%	-$29.2K	﹤0.01%	2332
2026 Q1	$641K	Sell	2,158 -9	-0.4%	-$2.91K	﹤0.01%	2129
2025 Q4	$658K	Buy	2,167 +1,377	+174%	+$451K	﹤0.01%	1933
2025 Q3	$269K	Buy	+790	New	+$240K	﹤0.01%	2350
2024 Q1	–	Sell	-2,174	Closed	-$392K	–	2365
2023 Q4	$392K	Sell	2,174 -97	-4%	-$17.5K	﹤0.01%	1379
2023 Q3	$408K	Sell	2,271 -202	-8%	-$40K	﹤0.01%	1042
2023 Q2	$441K	Sell	2,473 -449	-15%	-$103K	﹤0.01%	1236
2023 Q1	$630K	Buy	2,922 +152	+5%	+$36.5K	﹤0.01%	1184
2022 Q4	$609K	Buy	+2,770	New	+$508K	﹤0.01%	856

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cerity Partners's ONC Position: Q2 2026 in Review

Cerity Partners reduced its BeOne Medicines Ltd (ONC) stake by 4.6% in Q2 2026, selling an estimated $29.2K and leaving 2,059 shares worth $587K. The position accounts for ﹤0.01% of the portfolio, ranked #2332.

Cerity Partners first reported a position in ONC in Q4 2022 and has held it in 9 quarters since. The position peaked at $658K in Q4 2025. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Cerity Partners held 2,059 shares of BeOne Medicines Ltd worth $587K as of Q2 2026.
Cerity Partners sold 99 BeOne Medicines Ltd shares in Q2 2026, an estimated $29.2K.
BeOne Medicines Ltd made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2332 holding.
Cerity Partners first reported a position in BeOne Medicines Ltd in Q4 2022 and has held it in 9 quarters since.
Cerity Partners's BeOne Medicines Ltd position peaked at $658K in Q4 2025.
283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.